New drug cocktail aims at resistant lung cancer

NCT ID NCT07632209

Not yet recruiting Disease control Sponsor: Yayi He Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining two drugs, lomustine and anlotinib, can shrink tumors or slow disease in people with extensive-stage small cell lung cancer that has not responded to at least two prior treatments. About 46 participants will receive the drug combination by mouth. The study will measure how many patients respond and how long they stay progression-free, while also tracking side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lomustine and anlotinib
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced small cell lung cancer that has stopped responding to standard therapies.
What could go wrong: This is a small, early-phase trial with only 46 participants and no comparison group. The drug combination may cause side effects and might not improve outcomes significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLC, EXTENSIVE STAGE

More trials for these conditions

Other studies related to the condition(s) this trial covers.